Drug intelligence / Profile preview

AZ13754366

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

AZ13754366 is a radiolabeled compound used as a **positron emission tomography (PET) radioligand**. In clinical research, [11C]AZ13754366 enables visualization and measurement of muscarinic receptor occupancy in human lungs, primarily for the basic science investigation of inhaled muscarinic antagonists, such as AZD2115 and tiotropium. It is not a therapeutic agent itself and does not have direct disease-modifying or pharmacological activity, but serves as an imaging tool in early-phase clinical trials.

Other names: [11C]AZ13754366

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on AZ13754366.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZ13754366.

Explore the full profile